title: Persistence of macroprolactinemia due to antiprolactin autoantibody before, during, and after pregnancy in a woman with systemic lupus erythematosus.
abstract: A woman with systemic lupus erythematosus (SLE) with marked increases in circulating 150-kDa PRL was studied from before conception, throughout pregnancy, and after pregnancy. The clinical features of the patient included idiopathic hyperprolactinemia without clinical symptoms such as amenorrhea and galactorrhea before pregnancy. No clinical lupus activity was present during follow-up. Serum PRL increase during pregnancy in this patient was considerably higher at weeks 27 and 33 than in normal pregnant women. In contrast, serum-free PRL levels were considerably lower at weeks 20, 27, and 33 than in normal pregnant women. A 150-kDa PRL (big big PRL) species persisted as the predominant circulating form of PRL throughout each measurement in this woman with SLE. In contrast, the predominant form of PRL in serum from healthy pregnant women was little PRL (or monomeric PRL). The nature of big big PRL was due to the presence of anti-PRL autoantibodies forming an IgG-23 kDa PRL complex, in accordance with the studies by affinity chromatography for IgG and Western blot analysis. The IgG-PRL complex was fully bioactive in vitro (Nb2 rat lymphoma cell assay). Injection of the serum into the rats demonstrated that the IgG-PRL complex was cleared more slowly than serum containing predominantly monomeric PRL. The data suggest that the IgG-PRL complex has biological activity; the absence of symptoms in this woman may be attributed to the fact that due to its large molecular weight, big big PRL does not easily cross the capillary walls. Delayed clearance may account for increased serum PRL levels in this SLE patient with anti-PRL autoantibodies.
authors.affiliation: Laboratory of Autoimmunity, Immunology Research Unit, Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México City, 06725 México. alfredo@intranet.com.mx
authors.forename: A
authors.initials: A
authors.lastname: Leaños-Miranda
authors.forename: D
authors.initials: D
authors.lastname: Pascoe-Lira
authors.forename: K A
authors.initials: KA
authors.lastname: Chávez-Rueda
authors.forename: F
authors.initials: F
authors.lastname: Blanco-Favela
mesh_terms: D000328:Adult; D001323:Autoantibodies / Q000276:immunology*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000276:immunology*; D008180:Lupus Erythematosus, Systemic / Q000097:blood* / Q000276:immunology; D049590:Postpartum Period / Q000276:immunology*; D011247:Pregnancy / Q000097:blood / Q000276:immunology*; D011248:Pregnancy Complications; D011388:Prolactin / Q000276:immunology*
chemical_list: D001323:Autoantibodies; C060678:prolactin, polymeric; D011388:Prolactin